We are a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The widespread availability of approved targeted oncology treatments, such as kinase inhibitors, has transformed the cancer treatment landscape. Despite the therapeutic benefit that targeted oncology treatments have created for some patients, the response rate and duration of efficacy is often limited by acquired drug resistance and other shortcomings of existing therapies. We are using our proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options.
We are initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Our lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. We anticipate filing an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, for TYRA-300 in mid-2022. In addition, we have pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, or RET, and FGFR4-related cancers.
(Note: Tyra BioSciences increased the size of its IPO at pricing on Sept. 14, 2021, to 10.8 million shares – up from 9 million – and priced the IPO at $16 – the top of its $14-to-$16 range. Early Tuesday, Sept. 14, 2021, in an S-1/A filing with that date, the company increased the number of shares to 9 million – up from 6. 7 million initially – and kept the price range at $14 to $16.)
|Address||2656 State Street Carlsbad, CA 92008|
|Phone Number||(619) 728-4760|
|View Prospectus:||Tyra Biosciences|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-15.7 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$172.8 mil|
|Manager / Joint Managers||BofA Securities/ Jefferies/ Cowen and Company|
|Expected To Trade:||9/15/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|